India · Delayed Price · Currency is INR Aarti Pharmalabs Statistics
Total Valuation
NSE:AARTIPHARM has a market cap or net worth of INR 86.49 billion. The enterprise value is 94.33 billion.
| Market Cap | 86.49B |
| Enterprise Value | 94.33B |
Important Dates
The next estimated earnings date is Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
NSE:AARTIPHARM has 90.68 million shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 90.68M |
| Shares Outstanding | 90.68M |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 29.63% |
| Owned by Institutions (%) | 19.14% |
| Float | 49.92M |
Valuation Ratios
The trailing PE ratio is 42.28 and the forward PE ratio is 53.58.
| PE Ratio | 42.28 |
| Forward PE | 53.58 |
| PS Ratio | 4.39 |
| PB Ratio | 4.07 |
| P/TBV Ratio | 4.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 33.02 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 46.05 |
| EV / Sales | 4.79 |
| EV / EBITDA | 20.65 |
| EV / EBIT | 27.31 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.81 |
| Debt / FCF | -5.38 |
| Interest Coverage | 6.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.50% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.70% |
| Revenue Per Employee | 8.13M |
| Profits Per Employee | 846,010 |
| Employee Count | 2,421 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:AARTIPHARM has paid 683.45 million in taxes.
| Income Tax | 683.45M |
| Effective Tax Rate | 25.02% |
Stock Price Statistics
The stock price has increased by +17.88% in the last 52 weeks. The beta is 0.27, so NSE:AARTIPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +17.88% |
| 50-Day Moving Average | 813.49 |
| 200-Day Moving Average | 733.99 |
| Relative Strength Index (RSI) | 65.42 |
| Average Volume (20 Days) | 847,068 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:AARTIPHARM had revenue of INR 19.69 billion and earned 2.05 billion in profits. Earnings per share was 22.56.
| Revenue | 19.69B |
| Gross Profit | 10.67B |
| Operating Income | 3.28B |
| Pretax Income | 2.73B |
| Net Income | 2.05B |
| EBITDA | 4.40B |
| EBIT | 3.28B |
| Earnings Per Share (EPS) | 22.56 |
Balance Sheet
The company has 96.16 million in cash and 7.94 billion in debt, with a net cash position of -7.84 billion or -86.47 per share.
| Cash & Cash Equivalents | 96.16M |
| Total Debt | 7.94B |
| Net Cash | -7.84B |
| Net Cash Per Share | -86.47 |
| Equity (Book Value) | 21.25B |
| Book Value Per Share | 234.27 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 2.62 billion and capital expenditures -4.09 billion, giving a free cash flow of -1.47 billion.
| Operating Cash Flow | 2.62B |
| Capital Expenditures | -4.09B |
| Depreciation & Amortization | 1.11B |
| Net Borrowing | 2.46B |
| Free Cash Flow | -1.47B |
| FCF Per Share | -16.26 |
Margins
Gross margin is 54.19%, with operating and profit margins of 16.67% and 10.40%.
| Gross Margin | 54.19% |
| Operating Margin | 16.67% |
| Pretax Margin | 13.87% |
| Profit Margin | 10.40% |
| EBITDA Margin | 22.32% |
| EBIT Margin | 16.67% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 0.37%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 0.37% |
| Dividend Growth (YoY) | -30.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 15.51% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.11% |
| Shareholder Yield | 0.26% |
| Earnings Yield | 2.37% |
| FCF Yield | -1.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |